{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T06:51:50Z","timestamp":1794293510633,"version":"4.9.0"},"reference-count":151,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82071410"],"award-info":[{"award-number":["82071410"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82001335"],"award-info":[{"award-number":["82001335"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014718","name":"Innovative Research Group Project of the National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014718","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008750","name":"Shanghai Hospital Development Center","doi-asserted-by":"publisher","award":["SHDC2023CRD007"],"award-info":[{"award-number":["SHDC2023CRD007"]}],"id":[{"id":"10.13039\/501100008750","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.autrev.2025.103826","type":"journal-article","created":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T15:59:31Z","timestamp":1746287971000},"page":"103826","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Interleukin-6 in neuroimmunological disorders: Pathophysiology and therapeutic advances with satralizumab"],"prefix":"10.1016","volume":"24","author":[{"given":"Xicheng","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chongbo","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.autrev.2025.103826_bb0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2020.115327","article-title":"A panoramic review of IL-6: structure, pathophysiological roles and inhibitors","volume":"28","author":"Kaur","year":"2020","journal-title":"Bioorg Med Chem"},{"issue":"10","key":"10.1016\/j.autrev.2025.103826_bb0010","article-title":"IL-6 in inflammation, immunity, and disease","volume":"6","author":"Toshio","year":"2014","journal-title":"Cold Spring Harb. Perspect. Biol."},{"issue":"5","key":"10.1016\/j.autrev.2025.103826_bb0015","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/ni.3153","article-title":"IL-6 as a keystone cytokine in health and disease","volume":"16","author":"Hunter","year":"2015","journal-title":"Nat Immunol"},{"issue":"1","key":"10.1016\/j.autrev.2025.103826_bb0020","article-title":"IL-6 and related cytokines as the critical lynchpins between inflammation and cancer","volume":"26","author":"Koji","year":"2014","journal-title":"Semin Immunol"},{"issue":"8","key":"10.1016\/j.autrev.2025.103826_bb0025","article-title":"Interleukin (IL-6) immunotherapy","volume":"10","author":"Toshio","year":"2017","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"11","key":"10.1016\/j.autrev.2025.103826_bb0030","article-title":"Interleukin-6 signaling and anti-Interleukin-6 therapeutics in cardiovascular disease","volume":"128","author":"Paul","year":"2021","journal-title":"Circ Res"},{"issue":"0","key":"10.1016\/j.autrev.2025.103826_bb0035","article-title":"IL-6 as a major regulator of MDSC activity and possible target for cancer immunotherapy","volume":"359","author":"Rebekka","year":"2020","journal-title":"Cell Immunol"},{"issue":"14","key":"10.1016\/j.autrev.2025.103826_bb0040","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1007\/s40265-020-01380-2","article-title":"Satralizumab: First Approval","volume":"80","author":"Heo","year":"2020","journal-title":"Drugs"},{"issue":"5","key":"10.1016\/j.autrev.2025.103826_bb0045","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/S1474-4422(20)30078-8","article-title":"Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial","volume":"19","author":"Traboulsee","year":"2020","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.autrev.2025.103826_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.104025","article-title":"Long-term safety of satralizumab in neuromyelitis optica spectrum disorder (NMOSD) from SAkuraSky and SAkuraStar","volume":"66","author":"Yamamura","year":"2022","journal-title":"Mult Scler Relat Disord"},{"issue":"1","key":"10.1016\/j.autrev.2025.103826_bb0055","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200071","article-title":"Long-term efficacy of Satralizumab in AQP4-IgG-seropositive Neuromyelitis Optica Spectrum disorder from SAkuraSky and SAkuraStar","volume":"10","author":"Kleiter","year":"2023","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"2","key":"10.1016\/j.autrev.2025.103826_bb0060","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1474-4422(24)00514-3","article-title":"Safety and efficacy of satralizumab in patients with generalised myasthenia gravis (LUMINESCE): a randomised, double-blind, multicentre, placebo-controlled phase 3 trial","volume":"24","author":"Habib","year":"2025","journal-title":"The Lancet Neurology"},{"issue":"7","key":"10.1016\/j.autrev.2025.103826_bb0065","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1093\/rheumatology\/keu035","article-title":"Effects of IL-6 and IL-6 blockade on neutrophil function in vitro and in vivo","volume":"53","author":"Wright","year":"2014","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"10.1016\/j.autrev.2025.103826_bb0070","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/jid.2013.404","article-title":"IL-6 regulates neutrophil microabscess formation in IL-17A-driven psoriasiform lesions","volume":"134","author":"Croxford","year":"2014","journal-title":"J Invest Dermatol"},{"issue":"2","key":"10.1016\/j.autrev.2025.103826_bb0075","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1038\/s41423-020-00608-1","article-title":"Interleukin-6 mediates neutrophil mobilization from bone marrow in pulmonary hypertension","volume":"18","author":"Florentin","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.autrev.2025.103826_bb0080","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.intimp.2018.09.011","article-title":"Enhanced neutrophil autophagy and increased concentrations of IL-6, IL-8, IL-10 and MCP-1 in rheumatoid arthritis","volume":"65","author":"An","year":"2018","journal-title":"Int Immunopharmacol"},{"issue":"8","key":"10.1016\/j.autrev.2025.103826_bb0085","doi-asserted-by":"crossref","first-page":"5598","DOI":"10.4049\/jimmunol.181.8.5598","article-title":"Mast cell IL-6 improves survival from Klebsiella pneumonia and sepsis by enhancing neutrophil killing","volume":"181","author":"Sutherland","year":"2008","journal-title":"J Immunol"},{"issue":"2","key":"10.1016\/j.autrev.2025.103826_bb0090","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02248-2020","article-title":"Macrophage-derived IL-6 trans-signalling as a novel target in the pathogenesis of bronchopulmonary dysplasia","volume":"59","author":"Hirani","year":"2022","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.autrev.2025.103826_bb0095","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1186\/s12885-023-10826-1","article-title":"CAA-derived IL-6 induced M2 macrophage polarization by activating STAT3","volume":"23","author":"Zhao","year":"2023","journal-title":"BMC Cancer"},{"issue":"2","key":"10.1016\/j.autrev.2025.103826_bb0100","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.02049-21","article-title":"IL-6 prevents lung macrophage death and lung inflammation injury by inhibiting GSDME- and GSDMD-mediated Pyroptosis during pneumococcal Pneumosepsis","volume":"10","author":"Gou","year":"2022","journal-title":"Microbiol Spectr"},{"issue":"1","key":"10.1016\/j.autrev.2025.103826_bb0105","article-title":"PANoptosis-like death in acute-on-chronic liver failure injury","volume":"14","author":"Qianling","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.autrev.2025.103826_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2023.109660","article-title":"Molecular characterization of PANoptosis-related genes with features of immune dysregulation in systemic lupus erythematosus","volume":"253","author":"Sun","year":"2023","journal-title":"Clin Immunol"},{"key":"10.1016\/j.autrev.2025.103826_bb0115","article-title":"IL-6: regulator of Treg\/Th17 balance","volume":"40","author":"Akihiro","year":"2010","journal-title":"Eur J Immunol"},{"issue":"7","key":"10.1016\/j.autrev.2025.103826_bb0120","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1084\/jem.20120994","article-title":"The origins, function, and regulation of T follicular helper cells","volume":"209","author":"Ma","year":"2012","journal-title":"J Exp Med"},{"key":"10.1016\/j.autrev.2025.103826_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2022.215839","article-title":"Cancer-associated fibroblast-like fibroblasts in vocal fold leukoplakia suppress CD8(+)T cell functions by inducing IL-6 autocrine loop and interacting with Th17 cells","volume":"546","author":"Fang","year":"2022","journal-title":"Cancer Lett"},{"issue":"2","key":"10.1016\/j.autrev.2025.103826_bb0130","doi-asserted-by":"crossref","first-page":"140","DOI":"10.4254\/wjh.v16.i2.140","article-title":"Interleukins in liver disease treatment","volume":"16","author":"Yang","year":"2024","journal-title":"World J Hepatol"},{"issue":"2","key":"10.1016\/j.autrev.2025.103826_bb0135","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.4049\/jimmunol.169.2.1077","article-title":"Resistance to experimental autoimmune myasthenia gravis in IL-6-deficient mice is associated with reduced germinal center formation and C3 production","volume":"169","author":"Deng","year":"2002","journal-title":"J Immunol"},{"issue":"4","key":"10.1016\/j.autrev.2025.103826_bb0140","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1002\/cpt.782","article-title":"The soluble interleukin 6 receptor: advanced therapeutic options in inflammation","volume":"102","author":"Rose-John","year":"2017","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.autrev.2025.103826_bb0145","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1136\/ard-2022-223506","article-title":"Microglia activation in the presence of intact blood-brain barrier and disruption of hippocampal neurogenesis via IL-6 and IL-18 mediate early diffuse neuropsychiatric lupus","volume":"82","author":"Nikolopoulos","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103826_bb0150","article-title":"IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6","volume":"8","author":"Stefan","year":"2012","journal-title":"Int J Biol Sci"},{"issue":"12","key":"10.1016\/j.autrev.2025.103826_bb0155","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1038\/ni1406","article-title":"Fever-range thermal stress promotes lymphocyte trafficking across high endothelial venules via an interleukin 6 trans-signaling mechanism","volume":"7","author":"Chen","year":"2006","journal-title":"Nat Immunol"},{"key":"10.1016\/j.autrev.2025.103826_bb0160","first-page":"4","article-title":"Causal risk and protective factors in rheumatoid arthritis: a genetic update","author":"Arleevskaya","year":"2021","journal-title":"J Transl Autoimmun"},{"key":"10.1016\/j.autrev.2025.103826_bb0165","article-title":"Interleukin-6 trans-signaling and colonic cancer associated with inflammatory bowel disease","volume":"15","author":"Stefan","year":"2009","journal-title":"Curr Pharm Des"},{"issue":"7","key":"10.1016\/j.autrev.2025.103826_bb0170","doi-asserted-by":"crossref","first-page":"3755","DOI":"10.4049\/jimmunol.1302470","article-title":"Blockade of IL-6 trans signaling attenuates pulmonary fibrosis","volume":"193","author":"Le","year":"2014","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2025.103826_bb0175","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/j.biopha.2018.09.177","article-title":"The significant role of interleukin-6 and its signaling pathway in the immunopathogenesis and treatment of breast cancer","volume":"108","author":"Masjedi","year":"2018","journal-title":"Biomed Pharmacother"},{"issue":"10","key":"10.1016\/j.autrev.2025.103826_bb0180","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/s41577-023-00856-y","article-title":"Targeting IL-6 trans-signalling: past, present and future prospects","volume":"23","author":"Rose-John","year":"2023","journal-title":"Nat Rev Immunol"},{"issue":"7","key":"10.1016\/j.autrev.2025.103826_bb0185","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1053\/j.gastro.2021.02.062","article-title":"Therapeutic Interleukin-6 trans-signaling inhibition by Olamkicept (sgp130Fc) in patients with active inflammatory bowel disease","volume":"160","author":"Schreiber","year":"2021","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.autrev.2025.103826_bb0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.cytox.2021.100058","article-title":"Exclusive inhibition of IL-6 trans-signaling by soluble gp130(FlyR)fc","volume":"3","author":"Berg","year":"2021","journal-title":"Cytokine X"},{"issue":"5","key":"10.1016\/j.autrev.2025.103826_bb0195","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.bbamcr.2011.01.034","article-title":"The pro- and anti-inflammatory properties of the cytokine interleukin-6","volume":"1813","author":"Scheller","year":"2011","journal-title":"Biochim Biophys Acta"},{"issue":"21\u221222","key":"10.1016\/j.autrev.2025.103826_bb0200","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1089\/neu.2023.0135","article-title":"Interleukin-6 in traumatic brain injury: a Janus-faced player in damage and repair","volume":"40","author":"Ciryam","year":"2023","journal-title":"J Neurotrauma"},{"issue":"2","key":"10.1016\/j.autrev.2025.103826_bb0205","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.bja.2022.01.005","article-title":"Postoperative delirium and changes in the blood-brain barrier, neuroinflammation, and cerebrospinal fluid lactate: a prospective cohort study","volume":"129","author":"Taylor","year":"2022","journal-title":"Br J Anaesth"},{"issue":"7","key":"10.1016\/j.autrev.2025.103826_bb0210","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0101815","article-title":"Downregulation of blood-brain barrier phenotype by proinflammatory cytokines involves NADPH oxidase-dependent ROS generation: consequences for interendothelial adherens and tight junctions","volume":"9","author":"Rochfort","year":"2014","journal-title":"PloS One"},{"issue":"4","key":"10.1016\/j.autrev.2025.103826_bb0215","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1182\/blood-2007-05-091207","article-title":"STAT1 signaling modulates HIV-1-induced inflammatory responses and leukocyte transmigration across the blood-brain barrier","volume":"111","author":"Chaudhuri","year":"2008","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.autrev.2025.103826_bb0220","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1111\/jnc.13408","article-title":"Tumour necrosis factor-\u03b1-mediated disruption of cerebrovascular endothelial barrier integrity in vitro involves the production of proinflammatory interleukin-6","volume":"136","author":"Rochfort","year":"2016","journal-title":"J Neurochem"},{"issue":"1","key":"10.1016\/j.autrev.2025.103826_bb0225","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12987-023-00418-3","article-title":"Role of interleukin-6 and interleukin-10 in morphological and functional changes of the blood-brain barrier in hypertriglyceridemia","volume":"20","author":"Barabasi","year":"2023","journal-title":"Fluids Barriers CNS"},{"key":"10.1016\/j.autrev.2025.103826_bb0230","doi-asserted-by":"crossref","first-page":"1013933","DOI":"10.3389\/fnmol.2022.1013933","article-title":"New insight into neurological degeneration: inflammatory cytokines and blood-brain barrier","volume":"15","author":"Yang","year":"2022","journal-title":"Front Mol Neurosci"},{"issue":"3","key":"10.1016\/j.autrev.2025.103826_bb0235","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/nrneurol.2017.188","article-title":"Blood-brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders","volume":"14","author":"Sweeney","year":"2018","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.autrev.2025.103826_bb0240","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.neurobiolaging.2019.09.020","article-title":"Linking APOE-\u03b54, blood-brain barrier dysfunction, and inflammation to Alzheimer's pathology","volume":"85","author":"Riphagen","year":"2020","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.autrev.2025.103826_bb0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2023.578203","article-title":"Impact of blood-brain barrier disruption on clinical features and treatment response in patients with newly diagnosed autoimmune encephalitis","volume":"383","author":"Cheng","year":"2023","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.autrev.2025.103826_bb0250","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.biocel.2016.08.003","article-title":"Cell-specific paracrine actions of IL-6 family cytokines from bone, marrow and muscle that control bone formation and resorption","volume":"79","author":"Sims","year":"2016","journal-title":"Int J Biochem Cell Biol"},{"issue":"4","key":"10.1016\/j.autrev.2025.103826_bb0255","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.job.2022.10.001","article-title":"Histochemical assessment of accelerated bone remodeling and reduced mineralization in Il-6 deficient mice","volume":"64","author":"Moritani","year":"2022","journal-title":"J Oral Biosci"},{"issue":"17","key":"10.1016\/j.autrev.2025.103826_bb0260","doi-asserted-by":"crossref","DOI":"10.1172\/JCI152673","article-title":"Bone marrow-confined IL-6 signaling mediates the progression of myelodysplastic syndromes to acute myeloid leukemia","volume":"132","author":"Mei","year":"2022","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.autrev.2025.103826_bb0265","doi-asserted-by":"crossref","first-page":"4075","DOI":"10.1038\/s41467-020-17942-7","article-title":"Micro-environmental sensing by bone marrow stroma identifies IL-6 and TGF\u03b21 as regulators of hematopoietic ageing","volume":"11","author":"Valletta","year":"2020","journal-title":"Nat Commun"},{"issue":"5","key":"10.1016\/j.autrev.2025.103826_bb0270","article-title":"Repopulating microglia promote brain repair in an IL-6-dependent manner","volume":"180","author":"Emily","year":"2020","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.autrev.2025.103826_bb0275","article-title":"Oncostatin M triggers brain inflammation by compromising blood-brain barrier integrity","volume":"144","author":"Doryssa","year":"2022","journal-title":"Acta Neuropathol"},{"issue":"11","key":"10.1016\/j.autrev.2025.103826_bb0280","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/nrc2734","article-title":"STATs in cancer inflammation and immunity: a leading role for STAT3","volume":"9","author":"Yu","year":"2009","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"10.1016\/j.autrev.2025.103826_bb0285","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.pharmthera.2013.09.004","article-title":"Targeting interleukin-6 in inflammatory autoimmune diseases and cancers","volume":"141","author":"Yao","year":"2014","journal-title":"Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.autrev.2025.103826_bb0290","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.coi.2011.12.004","article-title":"Transcriptional mechanisms that regulate T helper 1 cell differentiation","volume":"24","author":"Oestreich","year":"2012","journal-title":"Curr Opin Immunol"},{"issue":"12","key":"10.1016\/j.autrev.2025.103826_bb0295","doi-asserted-by":"crossref","first-page":"872","DOI":"10.4049\/immunohorizons.2100112","article-title":"IL-6\/STAT3 signaling Axis enhances and prolongs Pdcd1 expression in murine CD8 T cells","volume":"6","author":"Powell","year":"2022","journal-title":"Immunohorizons"},{"issue":"7","key":"10.1016\/j.autrev.2025.103826_bb0300","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1002\/art.41666","article-title":"Characterization and function of tumor necrosis factor and Interleukin-6-induced osteoclasts in rheumatoid arthritis","volume":"73","author":"Yokota","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2025.103826_bb0305","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115288","article-title":"Deficiency of HtrA4 in BeWo cells downregulates angiogenesis through IL-6\/JAK\/STAT3 signaling","volume":"166","author":"Pei","year":"2023","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"10.1016\/j.autrev.2025.103826_bb0310","doi-asserted-by":"crossref","DOI":"10.1016\/j.labinv.2022.100023","article-title":"IL-6 plays a critical role in stromal fibroblast RANKL induction and consequent Osteoclastogenesis in Ameloblastoma progression","volume":"103","author":"Yoshimoto","year":"2023","journal-title":"Lab Invest"},{"issue":"6","key":"10.1016\/j.autrev.2025.103826_bb0315","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s00018-022-04331-0","article-title":"Mettl14 mediates the inflammatory response of macrophages in atherosclerosis through the NF-kappaB\/IL-6 signaling pathway","volume":"79","author":"Zheng","year":"2022","journal-title":"Cell Mol Life Sci"},{"issue":"4","key":"10.1016\/j.autrev.2025.103826_bb0320","article-title":"Inflammatory cytokines and chemokines are synergistically induced in a ROS-dependent manner by a co-culture of corneal epithelial cells and neutrophil-like cells in the presence of particulate matter","volume":"13","author":"Zeng","year":"2024","journal-title":"Antioxidants (Basel)"},{"issue":"1","key":"10.1016\/j.autrev.2025.103826_bb0325","article-title":"The gateway reflex regulates tissue-specific autoimmune diseases","volume":"44","author":"Yuki","year":"2024","journal-title":"Inflamm Regen"},{"key":"10.1016\/j.autrev.2025.103826_bb0330","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1042\/bj20030407","article-title":"Principles of interleukin (IL)-6-type cytokine signalling and its regulation","volume":"374","author":"Heinrich","year":"2003","journal-title":"Biochem J"},{"key":"10.1016\/j.autrev.2025.103826_bb0335","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.587913","article-title":"Lactate suppresses macrophage pro-inflammatory response to LPS stimulation by inhibition of YAP and NF-\u03baB activation via GPR81-mediated signaling","volume":"11","author":"Yang","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2025.103826_bb0340","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2022.215751","article-title":"Exosome-derived FGD5-AS1 promotes tumor-associated macrophage M2 polarization-mediated pancreatic cancer cell proliferation and metastasis","volume":"548","author":"He","year":"2022","journal-title":"Cancer Lett"},{"issue":"8","key":"10.1016\/j.autrev.2025.103826_bb0345","doi-asserted-by":"crossref","first-page":"4207","DOI":"10.1039\/D4FO00610K","article-title":"Astaxanthin targets IL-6 and alleviates the LPS-induced adverse inflammatory response of macrophages","volume":"15","author":"Wu","year":"2024","journal-title":"Food Funct"},{"key":"10.1016\/j.autrev.2025.103826_bb0350","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.110105","article-title":"Klotho alleviates contrast-induced acute kidney injury by suppressing oxidative stress, inflammation, and NF-KappaB\/NLRP3-mediated pyroptosis","volume":"118","author":"Fu","year":"2023","journal-title":"Int Immunopharmacol"},{"issue":"11","key":"10.1016\/j.autrev.2025.103826_bb0355","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1111\/1440-1681.13709","article-title":"Shikonin ameliorates oxidative stress and neuroinflammation via the Akt\/ERK\/JNK\/NF-\u03baB signalling pathways in a model of Parkinson's disease","volume":"49","author":"Guo","year":"2022","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1016\/j.autrev.2025.103826_bb0360","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.111732","article-title":"Modulation of the crosstalk between Keap1\/Nrf2\/HO-1 and NF-\u03baB signaling pathways by Tomatidine protects against inflammation\/oxidative stress-driven fulminant hepatic failure in mice","volume":"130","author":"Abdulaal","year":"2024","journal-title":"Int Immunopharmacol"},{"issue":"4","key":"10.1016\/j.autrev.2025.103826_bb0365","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s00408-016-9879-y","article-title":"Inflammatory mediators and oxidative stress in animals subjected to smoke inhalation: a systematic review","volume":"194","author":"de Carvalho","year":"2016","journal-title":"Lung"},{"issue":"2","key":"10.1016\/j.autrev.2025.103826_bb0370","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Dean","year":"2015","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.autrev.2025.103826_bb0375","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/nan.12574","article-title":"Review: recent advances in the understanding of the pathophysiology of neuromyelitis optica spectrum disorder","volume":"46","author":"Chang","year":"2020","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"8","key":"10.1016\/j.autrev.2025.103826_bb0380","doi-asserted-by":"crossref","DOI":"10.3390\/ijms17081306","article-title":"Neuroimmunological implications of AQP4 in astrocytes","volume":"17","author":"Ikeshima-Kataoka","year":"2016","journal-title":"Int J Mol Sci"},{"issue":"9","key":"10.1016\/j.autrev.2025.103826_bb0385","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0238301","article-title":"Purified IgG from aquaporin-4 neuromyelitis optica spectrum disorder patients alters blood-brain barrier permeability","volume":"15","author":"Cobo-Calvo","year":"2020","journal-title":"PloS One"},{"issue":"12","key":"10.1016\/j.autrev.2025.103826_bb0390","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1177\/1352458510379247","article-title":"Cytokine and chemokine profiles in neuromyelitis optica: significance of interleukin-6","volume":"16","author":"Uzawa","year":"2010","journal-title":"Mult Scler"},{"issue":"8","key":"10.1016\/j.autrev.2025.103826_bb0395","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1177\/1352458516672015","article-title":"Increased cerebrospinal fluid metalloproteinase-2 and interleukin-6 are associated with albumin quotient in neuromyelitis optica: their possible role on blood-brain barrier disruption","volume":"23","author":"Uchida","year":"2017","journal-title":"Mult Scler"},{"issue":"9","key":"10.1016\/j.autrev.2025.103826_bb0400","doi-asserted-by":"crossref","first-page":"3701","DOI":"10.1073\/pnas.1017385108","article-title":"Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica","volume":"108","author":"Chihara","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.autrev.2025.103826_bb0405","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2022.577925","article-title":"IL-6 as a marker for NMOSD disease activity","volume":"370","author":"Haramati","year":"2022","journal-title":"J Neuroimmunol"},{"issue":"5","key":"10.1016\/j.autrev.2025.103826_bb0410","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1159\/000339302","article-title":"Notable increased cerebrospinal fluid levels of soluble interleukin-6 receptors in neuromyelitis optica","volume":"19","author":"Wang","year":"2012","journal-title":"Neuroimmunomodulation"},{"issue":"1\u20132","key":"10.1016\/j.autrev.2025.103826_bb0415","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.jns.2013.05.035","article-title":"NMO sera down-regulate AQP4 in human astrocyte and induce cytotoxicity independent of complement","volume":"331","author":"Haruki","year":"2013","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.autrev.2025.103826_bb0420","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.118217","article-title":"Effect of NMO-IgG on the interleukin-6 cascade in astrocytes via activation of the JAK\/STAT3 signaling pathway","volume":"258","author":"Du","year":"2020","journal-title":"Life Sci"},{"issue":"1","key":"10.1016\/j.autrev.2025.103826_bb0425","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000311","article-title":"Effects of neuromyelitis optica-IgG at the blood-brain barrier in vitro","volume":"4","author":"Takeshita","year":"2017","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"11","key":"10.1016\/j.autrev.2025.103826_bb0430","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1084\/jem.20170523","article-title":"PTEN drives Th17 cell differentiation by preventing IL-2 production","volume":"214","author":"Kim","year":"2017","journal-title":"J Exp Med"},{"issue":"1","key":"10.1016\/j.autrev.2025.103826_bb0435","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/ana.23651","article-title":"Aquaporin 4-specific T cells in neuromyelitis optica exhibit a Th17 bias and recognize Clostridium ABC transporter","volume":"72","author":"Varrin-Doyer","year":"2012","journal-title":"Ann Neurol"},{"issue":"1","key":"10.1016\/j.autrev.2025.103826_bb0440","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s10875-012-9780-2","article-title":"The ex vivo production of IL-6 and IL-21 by CD4+ T cells is directly associated with neurological disability in neuromyelitis optica patients","volume":"33","author":"Linhares","year":"2013","journal-title":"J Clin Immunol"},{"issue":"1","key":"10.1016\/j.autrev.2025.103826_bb0445","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200173","article-title":"Long-term effects of IL-6 receptor blockade therapy on regulatory lymphocytes and neutrophils in Neuromyelitis Optica Spectrum disorder","volume":"11","author":"Matsuoka","year":"2024","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"6","key":"10.1016\/j.autrev.2025.103826_bb0450","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1002\/ana.22551","article-title":"Ex vivo spinal cord slice model of neuromyelitis optica reveals novel immunopathogenic mechanisms","volume":"70","author":"Zhang","year":"2011","journal-title":"Ann Neurol"},{"key":"10.1016\/j.autrev.2025.103826_bb0455","article-title":"A novel histone deacetylase inhibitor protects the blood-brain barrier by regulating NF-\u03baB and Nrf2 signaling pathways in OGD\/R injury","volume":"131","author":"Ling","year":"2024","journal-title":"Arch Gerontol Geriatr"},{"issue":"1","key":"10.1016\/j.autrev.2025.103826_bb0460","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1038\/s41598-025-85144-6","article-title":"Pterostilbene protects against lipopolysaccharide-induced inflammation and blood-brain barrier disruption in immortalized brain endothelial cell lines in vitro","volume":"15","author":"Zhou","year":"2025","journal-title":"Sci Rep"},{"key":"10.1016\/j.autrev.2025.103826_bb0465","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.neuroscience.2022.05.038","article-title":"NMO-IgG induce Interleukin-6 release via activation of the NF-kappaB signaling pathway in astrocytes","volume":"496","author":"Wang","year":"2022","journal-title":"Neuroscience"},{"issue":"2","key":"10.1016\/j.autrev.2025.103826_bb0470","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S1474-4422(21)00297-0","article-title":"Epidemiology, diagnostics, and biomarkers of autoimmune neuromuscular junction disorders","volume":"21","author":"Punga","year":"2022","journal-title":"Lancet Neurol"},{"issue":"1","key":"10.1016\/j.autrev.2025.103826_bb0475","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s12974-022-02448-4","article-title":"Independent risk factors for myasthenic crisis and disease exacerbation in a retrospective cohort of myasthenia gravis patients","volume":"19","author":"Nelke","year":"2022","journal-title":"J Neuroinflammation"},{"issue":"2","key":"10.1016\/j.autrev.2025.103826_bb0480","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/ana.22312","article-title":"Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis","volume":"69","author":"Higuchi","year":"2011","journal-title":"Ann Neurol"},{"key":"10.1016\/j.autrev.2025.103826_bb0485","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2023.106790","article-title":"Autoimmunity to neuronal nicotinic acetylcholine receptors","volume":"192","author":"Pechlivanidou","year":"2023","journal-title":"Pharmacol Res"},{"issue":"1","key":"10.1016\/j.autrev.2025.103826_bb0490","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","article-title":"Myasthenia gravis","volume":"5","author":"Gilhus","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.autrev.2025.103826_bb0495","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1196\/annals.1254.039","article-title":"Pathogenesis of myositis and myasthenia associated with titin and ryanodine receptor antibodies","volume":"998","author":"Skeie","year":"2003","journal-title":"Ann N Y Acad Sci"},{"issue":"1\u20132","key":"10.1016\/j.autrev.2025.103826_bb0500","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S0165-5728(00)00394-5","article-title":"Complement activation by titin and ryanodine receptor autoantibodies in myasthenia gravis. A study of IgG subclasses and clinical correlations","volume":"111","author":"Romi","year":"2000","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.autrev.2025.103826_bb0505","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1600-0404.2006.00608.x","article-title":"Titin and ryanodine receptor antibodies in myasthenia gravis","volume":"183","author":"Skeie","year":"2006","journal-title":"Acta Neurol Scand Suppl"},{"issue":"6","key":"10.1016\/j.autrev.2025.103826_bb0510","doi-asserted-by":"crossref","DOI":"10.3390\/cells13060508","article-title":"Recombinant acetylcholine receptor immunization induces a robust model of experimental autoimmune myasthenia gravis in mice","volume":"13","author":"Theissen","year":"2024","journal-title":"Cells"},{"issue":"9","key":"10.1016\/j.autrev.2025.103826_bb0515","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.autrev.2013.03.003","article-title":"Complement associated pathogenic mechanisms in myasthenia gravis","volume":"12","author":"Tuzun","year":"2013","journal-title":"Autoimmun Rev"},{"issue":"2","key":"10.1016\/j.autrev.2025.103826_bb0520","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1017\/cjn.2021.508","article-title":"Complement inhibition in myasthenia gravis and Neuromyelitis Optica Spectrum disorder","volume":"50","author":"Dodig","year":"2023","journal-title":"Can J Neurol Sci"},{"key":"10.1016\/j.autrev.2025.103826_bb0525","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2021.577634","article-title":"High levels of serum interleukin-6 are associated with disease activity in myasthenia gravis","volume":"358","author":"Uzawa","year":"2021","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.autrev.2025.103826_bb0530","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40478-014-0179-6","article-title":"IL-6 and Akt are involved in muscular pathogenesis in myasthenia gravis","volume":"3","author":"Maurer","year":"2015","journal-title":"Acta Neuropathol Commun"},{"key":"10.1016\/j.autrev.2025.103826_bb0535","first-page":"18","article-title":"Soluble adhesion molecules and cytokines in patients with myasthenia gravis treated by plasma exchange","author":"Tesa","year":"2000","journal-title":"Blood Purif"},{"key":"10.1016\/j.autrev.2025.103826_bb0540","first-page":"50","article-title":"Acetylcholine receptor-reactive T cells in myasthenia gravis: evidence for the involvement of different subpopulations of T helper cells","author":"Yi","year":"1994","journal-title":"J Neuroimmunol"},{"issue":"7","key":"10.1016\/j.autrev.2025.103826_bb0545","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.4049\/jimmunol.1500725","article-title":"Augmentation of circulating follicular helper T cells and their impact on autoreactive B cells in myasthenia gravis","volume":"197","author":"Zhang","year":"2016","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2025.103826_bb0550","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2020.108492","article-title":"Circulating Th1\/17 cells serve as a biomarker of disease severity and a target for early intervention in AChR-MG patients","volume":"218","author":"Ma","year":"2020","journal-title":"Clin Immunol"},{"issue":"7","key":"10.1016\/j.autrev.2025.103826_bb0555","doi-asserted-by":"crossref","DOI":"10.3390\/cells9071611","article-title":"Identification of novel molecular markers of human Th17 cells","volume":"9","author":"Sa\u0142kowska","year":"2020","journal-title":"Cells"},{"issue":"2","key":"10.1016\/j.autrev.2025.103826_bb0560","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jaut.2010.12.001","article-title":"Blocking of IL-6 suppresses experimental autoimmune myasthenia gravis","volume":"36","author":"Aricha","year":"2011","journal-title":"J Autoimmun"},{"issue":"4","key":"10.1016\/j.autrev.2025.103826_bb0565","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/j.1748-1716.2011.02281.x","article-title":"Skeletal muscle mass recovery from atrophy in IL-6 knockout mice","volume":"202","author":"Washington","year":"2011","journal-title":"Acta Physiol (Oxf)"},{"issue":"1","key":"10.1016\/j.autrev.2025.103826_bb0570","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1006\/bbrc.1995.1168","article-title":"Muscle undergoes atrophy in association with increase of lysosomal cathepsin activity in interleukin-6 transgenic mouse","volume":"207","author":"Tsujinaka","year":"1995","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"10.1016\/j.autrev.2025.103826_bb0575","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1172\/JCI118398","article-title":"Interleukin 6 receptor antibody inhibits muscle atrophy and modulates proteolytic systems in interleukin 6 transgenic mice","volume":"97","author":"Tsujinaka","year":"1996","journal-title":"J Clin Invest"},{"key":"10.1016\/j.autrev.2025.103826_bb0580","series-title":"The JAK1\/3 inhibitor tofacitinib regulates Th cell profiles and humoral immune responses in myasthenia gravis","author":"Bi","year":"2023"},{"key":"10.1016\/j.autrev.2025.103826_bb0585","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.109693","article-title":"JAK2 inhibitor ameliorates the progression of experimental autoimmune myasthenia gravis and balances Th17\/Treg cells via regulating the JAK2\/STAT3-AKT\/mTOR signaling pathway","volume":"115","author":"Lu","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.autrev.2025.103826_bb0590","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2021.577787","article-title":"Berberine attenuates experimental autoimmune myasthenia gravis via rebalancing the T cell subsets","volume":"362","author":"Song","year":"2022","journal-title":"J Neuroimmunol"},{"issue":"3","key":"10.1016\/j.autrev.2025.103826_bb0595","doi-asserted-by":"crossref","first-page":"E12","DOI":"10.1002\/mus.25458","article-title":"Remission of myasthenia gravis with MuSK antibodies during ruxolitinib treatment","volume":"55","author":"Alboini","year":"2017","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.autrev.2025.103826_bb0600","doi-asserted-by":"crossref","first-page":"104037","DOI":"10.1016\/j.msard.2022.104037","article-title":"Satralizumab might not be enough. Olamkicept (sgp130Fc) in Neuromyelitis Optica Spectrum Disorder","volume":"65","author":"Magro","year":"2022","journal-title":"Mult Scler Relat Disord"},{"issue":"6","key":"10.1016\/j.autrev.2025.103826_bb0605","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000001076","article-title":"New BBB model reveals that IL-6 blockade suppressed the BBB disorder, preventing onset of NMOSD","volume":"8","author":"Takeshita","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.autrev.2025.103826_bb0610","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103772","article-title":"Exploring steroid tapering in patients with neuromyelitis optica spectrum disorder treated with satralizumab in SAkuraSky: a case series","volume":"61","author":"Yamamura","year":"2022","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.autrev.2025.103826_bb0615","first-page":"9","article-title":"Demystifying MOGAD and double seronegative NMOSD further with IL-6 blockade","author":"Kok Pin","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"22","key":"10.1016\/j.autrev.2025.103826_bb0620","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1056\/NEJMoa1901747","article-title":"Trial of Satralizumab in Neuromyelitis Optica Spectrum disorder","volume":"381","author":"Yamamura","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2025.103826_bb0625","author":"Roche"},{"key":"10.1016\/j.autrev.2025.103826_bb0630","doi-asserted-by":"crossref","first-page":"1322412","DOI":"10.3389\/fneur.2023.1322412","article-title":"Neuromyelitis optica spectrum disorder safely and successfully treated with satralizumab during pregnancy and breastfeeding: a case report","volume":"14","author":"Yoshida","year":"2023","journal-title":"Front Neurol"},{"key":"10.1016\/j.autrev.2025.103826_bb0635","doi-asserted-by":"crossref","first-page":"1257955","DOI":"10.3389\/fimmu.2023.1257955","article-title":"Satralizumab as an add-on treatment in refractory pediatric AQP4-antibody-positive neuromyelitis optica spectrum disorder: a case report","volume":"14","author":"Li","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2025.103826_bb0640","doi-asserted-by":"crossref","first-page":"1114667","DOI":"10.3389\/fneur.2023.1114667","article-title":"SAkuraBONSAI: protocol design of a novel, prospective study to explore clinical, imaging, and biomarker outcomes in patients with AQP4-IgG-seropositive neuromyelitis optica spectrum disorder receiving open-label satralizumab","volume":"14","author":"Bennett","year":"2023","journal-title":"Front Neurol"},{"key":"10.1016\/j.autrev.2025.103826_bb0645","doi-asserted-by":"crossref","first-page":"S177","DOI":"10.1016\/j.nmd.2023.07.438","article-title":"Anti-IL-6 receptor antibody suppresses muscle atrophy in human myotube cells","volume":"33","author":"Miyake","year":"2023","journal-title":"Neuromuscul Disord"},{"issue":"20","key":"10.1016\/j.autrev.2025.103826_bb0650","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1212\/WNL.0b013e31825644ff","article-title":"Myasthenia gravis and neuromyelitis optica spectrum disorder: a multicenter study of 16 patients","volume":"78","author":"Leite","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2025.103826_bb0655","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102173","article-title":"Neuromyelitis optica in patients with myasthenia gravis: two case-reports","volume":"43","author":"Castro-Suarez","year":"2020","journal-title":"Mult Scler Relat Disord"},{"issue":"8","key":"10.1016\/j.autrev.2025.103826_bb0660","doi-asserted-by":"crossref","first-page":"584","DOI":"10.2174\/1871527319666200708133103","article-title":"Autoimmune encephalitis: current knowledge on subtypes, disease mechanisms and treatment","volume":"19","author":"Nissen","year":"2020","journal-title":"CNS Neurol Disord Drug Targets"},{"issue":"6","key":"10.1016\/j.autrev.2025.103826_bb0665","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S1474-4422(23)00083-2","article-title":"Diagnostic criteria for autoimmune encephalitis: utility and pitfalls for antibody-negative disease","volume":"22","author":"Dalmau","year":"2023","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.autrev.2025.103826_bb0670","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s12974-015-0293-9","article-title":"Astrocyte response to IFN-gamma limits IL-6-mediated microglia activation and progressive autoimmune encephalomyelitis","volume":"12","author":"Savarin","year":"2015","journal-title":"J Neuroinflammation"},{"key":"10.1016\/j.autrev.2025.103826_bb0675","author":"Roche"},{"issue":"0","key":"10.1016\/j.autrev.2025.103826_bb0680","article-title":"Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): a review of clinical and MRI features","volume":"13","author":"Elia","year":"2022","journal-title":"Diagnosis, and Management Front Neurol"},{"issue":"9","key":"10.1016\/j.autrev.2025.103826_bb0685","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1136\/jnnp-2018-317969","article-title":"CSF cytokine profile in MOG-IgG+ neurological disease is similar to AQP4-IgG+ NMOSD but distinct from MS: a cross-sectional study and potential therapeutic implications","volume":"89","author":"Kaneko","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.autrev.2025.103826_bb0690","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2020.577361","article-title":"Serum level of IL-1\u03b2 in patients with inflammatory demyelinating disease: marked upregulation in the early acute phase of MOG antibody associated disease (MOGAD)","volume":"348","author":"Kwon","year":"2020","journal-title":"J Neuroimmunol"},{"issue":"4","key":"10.1016\/j.autrev.2025.103826_bb0695","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200243","article-title":"Life-threatening MOG antibody-associated hemorrhagic ADEM with elevated CSF IL-6","volume":"11","author":"Virupakshaiah","year":"2024","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"1","key":"10.1016\/j.autrev.2025.103826_bb0700","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000001100","article-title":"Interleukin-6 receptor blockade in treatment-refractory MOG-IgG-associated disease and Neuromyelitis Optica Spectrum disorders","volume":"9","author":"Ringelstein","year":"2022","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"1","key":"10.1016\/j.autrev.2025.103826_bb0705","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/ene.13819","article-title":"Multiple sclerosis - a review","volume":"26","author":"Dobson","year":"2019","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.autrev.2025.103826_bb0710","doi-asserted-by":"crossref","first-page":"120","DOI":"10.3389\/fncel.2020.00120","article-title":"IL-6 in the cerebrospinal fluid signals disease activity in multiple sclerosis","volume":"14","author":"Stampanoni Bassi","year":"2020","journal-title":"Front Cell Neurosci"},{"issue":"6","key":"10.1016\/j.autrev.2025.103826_bb0715","first-page":"1104","article-title":"Interleukin-6 concentration in serum and cerebrospinal fluid in multiple sclerosis patients","volume":"6","author":"Stelmasiak","year":"2000","journal-title":"Med Sci Monit"},{"issue":"1","key":"10.1016\/j.autrev.2025.103826_bb0720","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0022-510X(96)00283-3","article-title":"IL-6 detection in multiple sclerosis brain","volume":"146","author":"Maimone","year":"1997","journal-title":"J Neurol Sci"},{"issue":"26","key":"10.1016\/j.autrev.2025.103826_bb0725","doi-asserted-by":"crossref","first-page":"9041","DOI":"10.1073\/pnas.0802218105","article-title":"IL-6 blockade inhibits the induction of myelin antigen-specific Th17 cells and Th1 cells in experimental autoimmune encephalomyelitis","volume":"105","author":"Serada","year":"2008","journal-title":"Proc Natl Acad Sci"},{"issue":"8","key":"10.1016\/j.autrev.2025.103826_bb0730","first-page":"934","article-title":"Detection of interleukin-6 in serum and cerebrospinal fluid of patients with neuroimmunological diseases","volume":"42","author":"Shimada","year":"1993","journal-title":"Arerugi"},{"issue":"2","key":"10.1016\/j.autrev.2025.103826_bb0735","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/jns.12622","article-title":"Cytokines and chemokines in patients with chronic inflammatory demyelinating polyradiculoneuropathy and multifocal motor neuropathy: a systematic review","volume":"29","author":"Cutelle","year":"2024","journal-title":"J Peripher Nerv Syst"},{"issue":"2","key":"10.1016\/j.autrev.2025.103826_bb0740","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/art.38246","article-title":"Interleukin-6 receptor blockade enhances CD39+ regulatory T cell development in rheumatoid arthritis and in experimental arthritis","volume":"66","author":"Thiolat","year":"2014","journal-title":"Arthritis Rheumatol"},{"issue":"12","key":"10.1016\/j.autrev.2025.103826_bb0745","doi-asserted-by":"crossref","first-page":"3710","DOI":"10.1002\/art.24126","article-title":"Interleukin-6 blockade suppresses autoimmune arthritis in mice by the inhibition of inflammatory Th17 responses","volume":"58","author":"Fujimoto","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.autrev.2025.103826_bb0750","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200266","article-title":"Interleukin-6 signaling blockade induces regulatory Plasmablasts in Neuromyelitis Optica Spectrum disorder","volume":"11","author":"Akatani","year":"2024","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"18","key":"10.1016\/j.autrev.2025.103826_bb0755","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.2169\/internalmedicine.9036-21","article-title":"Complete relief of painful tonic seizures in Neuromyelitis Optica Spectrum disorder by Satralizumab treatment","volume":"61","author":"Uzawa","year":"2022","journal-title":"Intern Med"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997225000862?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997225000862?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T19:07:02Z","timestamp":1749323222000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997225000862"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":151,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S1568997225000862"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2025.103826","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Interleukin-6 in neuroimmunological disorders: Pathophysiology and therapeutic advances with satralizumab","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2025.103826","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103826"}}